Articles & Video
eBook: Commercial-scale Production of mRNA and Oligonucleotides
We look at strategies for rapid deployment of mRNA manufacturing, oligonucleotide synthesis, navigating regulatory guidance and scaling up.
Report: Oligonucleotide, Peptide, mRNA and Genome Edited Therapeutics State of the Industry 2021
How has the oligonucleotide, peptide, mRNA and genome editing sector transformed over the last year? This industry report provides insight.
45% of companies in oligonucleotide, peptide and mRNA therapeutics increased collaboration during the pandemic
We examine the effects on collaboration in the peptide, oligonucleotide and mRNA therapeutics industry as a result of the COVID-19 pandemic.
TIDES Europe Virtual 2020: Post-event Report
This report looks back at the top sessions and features of this year's TIDES Europe Virtual.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
The Future of the Oligonucleotide and Peptide Therapeutics Industry
What changes could happen in the oligonucleotide and peptide therapeutics industry over the next decade? This interactive ebook gathers predictions from industry professionals all over the globe.
Oligonucleotides and peptides: the regulatory challenges
We investigate where current regulatory obstacles lie surrounding peptide and oligonucleotide therapeutics.
Strategies to Innovate the Production of Next Generation Bioconjugates
From developing ADCs to tumor-targeting, this whitepaper reviews the latest common challenges and novel strategies for producing bioconjugates.
Innovating CMC for Oligonucleotide and Peptide Therapeutics
In a new ebook, we look at ways to optimize chemistry manufacturing and controls for oligonucleotide and peptide therapeutics.
Partnering in the oligonucleotide and peptide therapeutics industry - WHITEPAPER
This whitepaper looks at the partnering challenges and opportunities facing the peptide and oligonucleotide therapeutics industry, using a number of case studies.
Manufacturing oligonucleotides: addressing safety and delivery challenges
We explore ways to tackle the main challenges in designing control strategies for oligonucleotide therapeutics.
Regulatory challenges and strategies for oligonucleotide, peptide and mRNA therapeutics - WHITEPAPER
We explore the regulatory challenges and successful approval strategies for oligonucleotide, peptide and mRNA therapeutics.
Drug delivery trends in oligo, peptide, mRNA and CRISPR therapeutics
What are the current strategies and technology demands in delivering oligos, peptides mRNA and CRISPR therapeutics? We find out from our recent survey data.
The future of peptide vaccines and personalized peptide therapies - WHITEPAPER
This whitepaper explores the exciting potential future of peptide vaccines and personalized peptide therapies.
REPORT: State of Oligo, Peptide, mRNA and CRISPR Therapeutics 2019
This exclusive report explores the state of the oligo, peptide, mRNA and CRISPR therapeutics industry in 2019 - download it here.
CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development - WHITEPAPER
This whitepaper explores the different CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development. Download it here.
Boosting commercialization of oligonucleotides as a raw materials supplier with Aldevron
Tom Lynch, Vice President of Sales & Client Development at Aldevron joined us at TIDES US in San Diego to discuss the company's role as a CDMO and how it is approaching the oligonucleotides market as a critical raw materials supplier.
Drug Delivery of Oligonucleotides, Peptides, RNA, mRNA and CRISPR - WHITEPAPER
This whitepaper explores the latest innovations, strategies and challenges of drug delivery of oligonucleotides, peptides, RNA, mRNA and CRISPR. Download it here.
Oligo collaboration: The European Pharmaceutical Oligonucleotide Consortium
Oligo collaboration is essential for the development of new therapeutics. Rachel Orr from GSK, discusses the launch of the European Pharmaceutical Oligonucleotide Consortium (EPOC).